Trial · NCT02600897
Results by group487
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 487
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants With Dose-Limiting Toxicities (DLTs) | Dose-escalation Phase: 1.4 mg Pola + 10 mg L + 1000 mg G in FL | 0.0 | percentage of participants | ||
| Percentage of Participants With Dose-Limiting Toxicities (DLTs) | Dose-escalation Phase: 1.8 mg Pola + 10 mg L + 1000 mg G in FL | 50.0 | percentage of participants | ||
| Percentage of Participants With Dose-Limiting Toxicities (DLTs) | Dose-escalation Phase: 1.4 mg Pola + 15 mg L + 1000 mg G in FL | 0.0 | percentage of participants | ||
| Percentage of Participants With Dose-Limiting Toxicities (DLTs) | Dose-escalation Phase: 1.4 mg Pola + 20 mg L + 1000 mg G in FL | 0.0 | percentage of participants | ||
| Percentage of Participants With Dose-Limiting Toxicities (DLTs) | Dose-escalation Phase: 1.8 mg Pola + 10 mg L + 375 mg R in DLBCL | 0.0 | percentage of participants | ||
| Percentage of Participants With Dose-Limiting Toxicities (DLTs) | Dose-escalation Phase: 1.8 mg Pola + 15 mg L + 375 mg R in DLBCL | 0.0 | percentage of participants | ||
| Percentage of Participants With Dose-Limiting Toxicities (DLTs) | Dose-escalation Phase: 1.8 mg Pola + 20 mg L + 375 mg R in DLBCL | 0.0 | percentage of participants | ||
| Percentage of Participants With Adverse Events (AEs) | Dose-escalation Phase: 1.4 mg Pola + 10 mg L + 1000 mg G in FL | 100.0 | percentage of participants | ||
| Percentage of Participants With Adverse Events (AEs) | Dose-escalation Phase: 1.8 mg Pola + 10 mg L + 1000 mg G in FL | 100.0 | percentage of participants | ||
| Percentage of Participants With Adverse Events (AEs) | Dose-escalation Phase: 1.4 mg Pola + 15 mg L + 1000 mg G in FL | 100.0 | percentage of participants | ||
| Percentage of Participants With Adverse Events (AEs) | Dose-escalation Phase: 1.4 mg Pola + 20 mg L + 1000 mg G in FL | 100.0 | percentage of participants | ||
| Percentage of Participants With Adverse Events (AEs) | Dose-escalation Phase: 1.8 mg Pola + 10 mg L + 375 mg R in DLBCL | 100.0 | percentage of participants | ||
| Percentage of Participants With Adverse Events (AEs) | Dose-escalation Phase: 1.8 mg Pola + 15 mg L + 375 mg R in DLBCL | 100.0 | percentage of participants | ||
| Percentage of Participants With Adverse Events (AEs) | Dose-escalation Phase: 1.8 mg Pola + 20 mg L + 375 mg R in DLBCL | 100.0 | percentage of participants | ||
| Percentage of Participants With Adverse Events (AEs) | Expansion Phase: 1.4 mg Pola + 20 mg L + 1000 mg G in FL | 100.0 | percentage of participants | ||
| Percentage of Participants With Adverse Events (AEs) | Expansion Phase: 1.8 mg Pola + 20 mg L + 375 mg R in DLBCL | 97.4 | percentage of participants | ||
Percentage of Participants With Complete Response (CR) at End of Induction (EOI), Determined by an Independent Review Committee (IRC) on the Basis of Positron Emission Tomography (PET) and Computed Tomography (CT) Scans | Dose-escalation Phase: 1.4 mg Pola + 20 mg L + 1000 mg G in FL | 66.7 | 90% Confidence Interval 27.13 to 93.72 | percentage of participants | |
Percentage of Participants With Complete Response (CR) at End of Induction (EOI), Determined by an Independent Review Committee (IRC) on the Basis of Positron Emission Tomography (PET) and Computed Tomography (CT) Scans | Dose-escalation Phase: 1.8 mg Pola + 20 mg L + 375 mg R in DLBCL | 0.0 | 90% Confidence Interval 0.0 to 25.89 | percentage of participants | |
Percentage of Participants With Complete Response (CR) at End of Induction (EOI), Determined by an Independent Review Committee (IRC) on the Basis of Positron Emission Tomography (PET) and Computed Tomography (CT) Scans | Expansion Phase: 1.4 mg Pola + 20 mg L + 1000 mg G in FL | 60.0 | 90% Confidence Interval 45.78 to 73.06 | percentage of participants | |
Percentage of Participants With Complete Response (CR) at End of Induction (EOI), Determined by an Independent Review Committee (IRC) on the Basis of Positron Emission Tomography (PET) and Computed Tomography (CT) Scans | Expansion Phase: 1.8 mg Pola + 20 mg L + 375 mg R in DLBCL | 38.5 | 90% Confidence Interval 25.41 to 52.89 | percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02600897/results